Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib with Arsenic Trioxide, Vitamin C, and Melphalan in Multiple Myeloma
NCT00469209Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2006
- Primary completion
- Dec 2008
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in multiple myeloma (MM), sponsored by University of Texas MD Anderson Cancer Center. Started Jun 2006; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00469209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00469209.